Literature DB >> 25419367

A chronic obstructive pulmonary disease negatively influences the prognosis of patients with bladder urothelial carcinoma via hypoxia inducible factor-1α.

Zhichao Huang1, Ran Xu1, Chen Lv2, Zhaohui Zhong1, Lei Zhang1, Liang Zhu1, Yongzhong Tang3, Xiaokun Zhao1.   

Abstract

OBJECTIVE: In this study, we investigated the relationship between the expression of hypoxia inducible factor-1α (HIF-1α) and tumor hypoxia, which is caused by chronic hypoxemic hypoxia in chronic obstructive pulmonary disease (COPD), and the prognostic value of COPD in patients with bladder urothelial carcinoma (BUC).
METHODS: The clinicopathological variables of 80 patients with BUC who underwent surgery were analyzed by retrospective methods. Overall survival (OS), disease-specific survival (DSS) and progression-free survival (PFS) were analyzed with clinicopathological variables including concomitant COPD, pulmonary function test (PFT), serum hemoglobin level and smoking history, using Kaplan-Meier survival analysis. The Cox proportional hazards regression model was used for multivariate analysis. The localization of HIF-1α expression was analyzed by immunohistochemistry.
RESULTS: Both the median OS and PFS of patients with COPD were shorter than the patients without COPD (P < 0.001). High levels of HIF-1α expression were associated with BUC of higher clinicopathological stage and histological grade (P < 0.001). COPD was an independent prognostic variable for OS, PFS and DSS. The clinicopathological stage was an independent prognostic variable for OS and DSS. The level of HIF-1α expression was an independent prognostic variable for PFS.
CONCLUSIONS: COPD is an independent prognostic variable for BUC, and contributes to poor prognosis.

Entities:  

Keywords:  Bladder urothelial carcinoma; chronic hypoxia; chronic obstructive pulmonary disease; hypoxia inducible factor-1α; prognosis

Year:  2014        PMID: 25419367      PMCID: PMC4238552     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  34 in total

Review 1.  Does smoking status influence the prognosis of bladder cancer? A systematic review.

Authors:  P Aveyard; P Adab; K K Cheng; D M A Wallace; K Hey; M F G Murphy
Journal:  BJU Int       Date:  2002-08       Impact factor: 5.588

2.  The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.

Authors:  Jane L Boddy; Stephen B Fox; Cheng Han; Leticia Campo; Helen Turley; Suresh Kanga; Peter R Malone; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

4.  Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.

Authors:  Rianne J M Lammers; Wim P J Witjes; Kees Hendricksen; Christien T M Caris; Maria H C Janzing-Pastors; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-07-14       Impact factor: 20.096

Review 5.  Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review).

Authors:  E Minet; G Michel; J Remacle; C Michiels
Journal:  Int J Mol Med       Date:  2000-03       Impact factor: 4.101

6.  Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species.

Authors:  Ning Gao; Min Ding; Jenny Z Zheng; Zhuo Zhang; Stephen S Leonard; Ke Jian Liu; Xianglin Shi; Bing-Hua Jiang
Journal:  J Biol Chem       Date:  2002-06-17       Impact factor: 5.157

7.  Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha.

Authors:  Denise A Chan; Patrick D Sutphin; Nicholas C Denko; Amato J Giaccia
Journal:  J Biol Chem       Date:  2002-08-16       Impact factor: 5.157

8.  Urinary system.

Authors:  C F Lynch; M B Cohen
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

9.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

10.  Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1.

Authors:  G L Semenza; B H Jiang; S W Leung; R Passantino; J P Concordet; P Maire; A Giallongo
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

View more
  4 in total

1.  Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.

Authors:  Chia-En Li; Chia-Shen Chien; Yao-Chi Chuang; Ye-In Chang; Hsiu-Pei Tang; Chih-Hsiung Kang
Journal:  Int Urol Nephrol       Date:  2016-03-19       Impact factor: 2.370

2.  Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway.

Authors:  Zhichao Huang; Zhaohui Zhong; Lei Zhang; Xinjun Wang; Ran Xu; Liang Zhu; Zijian Wang; Shanbiao Hu; Xiaokun Zhao
Journal:  Sci Rep       Date:  2015-08-04       Impact factor: 4.379

3.  Gene fingerprint model for literature based detection of the associations among complex diseases: a case study of COPD.

Authors:  Guocai Chen; Yuxi Jia; Lisha Zhu; Ping Li; Lin Zhang; Cui Tao; W Jim Zheng
Journal:  BMC Med Inform Decis Mak       Date:  2019-01-31       Impact factor: 2.796

Review 4.  Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review.

Authors:  Rui Batista; Nuno Vinagre; Sara Meireles; João Vinagre; Hugo Prazeres; Ricardo Leão; Valdemar Máximo; Paula Soares
Journal:  Diagnostics (Basel)       Date:  2020-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.